Pharming CEO Fabrice Chouraqui 离任，Leverne Marsh 与 Kenneth Lynard 出任临时联席 CEO
Pharming announces CEO transition
Pharming 宣布 CEO 兼执行董事 Fabrice Chouraqui 即刻离任，董事会与其就公司下一阶段战略推进方式存在分歧，双方协商一致进行领导层交接。首席商务官 Leverne Marsh 与首席财务官 Kenneth Lynard 即刻出任临时联席 CEO，分别负责患者相关业务与全球公司职能，董事会已启动永久继任者的正式遴选。公司表示战略、管线及对患者的承诺不变。
Leiden, the Netherlands, September 29, 2026: Pharming (Euronext Amsterdam: PHARM/Nasdaq: PHAR), a global biotechnology company focused on rare immune and genetic diseases, today announced that the Board of Directors and Fabrice Chouraqui have mutually agreed that Mr. Chouraqui will step down as Chief Executive Officer and Executive Director, with immediate effect.
To ensure continuity of leadership, the Board of Directors has appointed Mrs. Leverne Marsh, Chief Commercial Officer, and Mr. Kenneth Lynard, Chief Financial Officer, as Interim Co-CEOs, effective immediately. Mrs. Marsh will lead the patient-focused operations while Mr. Lynard will lead the global corporate functions. The Board has started a formal search for a permanent successor.
Following discussions about the execution of Pharming's strategic priorities for the next phase of the company, the Board of Directors and Mr. Chouraqui have concluded that their views on how to advance the company's strategy are not sufficiently aligned. In good consultation, the parties have therefore agreed on a leadership transition.
Pharming’s strategy, pipeline and commitment to patients remain unchanged. Focus remains on executing the strategic priorities and advancing the next phase of growth.
“On behalf of the Board, I would like to express our appreciation for Mr. Chouraqui’s contributions. We wish him well on his next endeavors,” said Richard Peters, Chairman of the Board of Directors of Pharming. “Our immediate priority is to ensure continuity across leadership, while maintaining focus on the continued execution of Pharming’s strategy and its commitment to patients.”
Fabrice Chouraqui added: “It has been a privilege to lead Pharming and to work alongside colleagues who are deeply committed to improving the lives of people with rare diseases. I have continually been inspired by the unwavering patient focus of our teams around the world and am deeply grateful for the passion and dedication they bring to our shared purpose every day. I leave with great confidence in their ability to continue expanding Pharming’s impact for patients and their families.”
To support an orderly transition process, Pharming and Mr. Chouraqui will not comment further beyond this announcement.
来源：Pharming Group｜法明 · pharming.com